The ongoing coronavirus disease 2019 (COVID-19) pandemic caused by the novel severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) accelerates the discovery of …

Background: Increasing clinical evidence suggests that people with severe mental illness
(SMI), including schizophrenia spectrum disorders, bipolar disorder (BD), and major …

Repurposing drugs as treatments for COVID-19, the disease caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), has drawn much attention. Beginning …

As new pathogens emerge, new challenges must be faced. This is no different in infectious
disease research, where identifying the best tools available in laboratories to conduct an …

Several medications commonly used for a number of medical conditions share a property of
functional inhibition of acid sphingomyelinase (ASM), or FIASMA. Preclinical and clinical …

Long COVID refers to the lingering symptoms which persist or appear after the acute illness.
The dominant long COVID symptoms in the two years since the pandemic began (2020 …

Repurposing of currently available drugs is a valuable strategy to tackle the consequences
of COVID-19. Recently, several studies have investigated the effect of psychoactive drugs on …

Since the first reports from December 2019, COVID-19 caused an overwhelming global
pandemic that has affected 223 countries, seriously endangering public health and creating …

Introduction: Despite the availability of new vaccines for SARS-CoV-2, there has been slow
uptake and problems with supply in some parts of the world. Hence, there is still a necessity …

Monoclonal antibody (mAb) therapy is one of the most promising immunotherapies that have
shown the potential to prevent or neutralize the effects of COVID-19 in patients at very early …